As per the merger, Sarah Cannon and Genospace will use molecular profiling data to more effectively match cancer patients to new therapies in clinical trials. Genospace will offers its precision medicine platform and enhance it to allow analysis of disparate data from clinical and laboratory sources. The technology will be integrated into Sarah Cannon’s network of oncology programs across the United States and United Kingdom.
Additionally, Genospace’s platform provides patient-facing portals and disease-specific communities for patient education.
“Bringing together the expertise of Sarah Cannon’s physicians coupled with our leadership in molecular data integration and interpretation, we can impact the lives of hundreds of thousands of patients,” said Mick Correll, CEO at Genospace.
More articles on health IT:
The most common reasons IT pros are fired
Survey: 30% of CIOs name IT security as top concern for 2017
Study: Patient symptoms ‘inconsistent’ between EMR documentation, self-reported questionnaire
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
